MedImmune partner to progress cancer immunotherapy research The Cancer Research Institute.

CRI, MedImmune partner to progress cancer immunotherapy research The Cancer Research Institute , the Ludwig Institute for Malignancy MedImmune and Research, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the study of immunotherapy in cancer. Specifically, the study will focus on clinical trials to test novel combos of immunotherapies, including three investigational monoclonal antibodies from MedImmune’s pipeline medication side effects . Therapeutic strategies that seek to recalibrate and amplify a patient’s disease fighting capability to better recognize and attack cancers are quickly gaining momentum. In the last few years, approvals of this new class of remedies called immunotherapy possess laid a strong foundation for a new wave of more effective immune system-based medicines that may offer greater clinical advantage for a more substantial %age of cancer patients.